[Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Progress in molecular biology has facilitated a new classification for melanoma. Melanomas today are considered as a heterogeneous group of tumors. The different subtypes are characterized by specific genetic alterations, including mutations in kinase, such as B-RAF or c-kit. New medications like vemurafenib have been developed and are available for the systemic therapy of advanced melanomas in subpopulations identified by mutation tests. In addition, interferon therapy holds the highest promises to dates in subpopulations of patients characterized by microscopic lymph node involvement and ulceration of the primary tumor. These developments are the first steps resulting in a personalized treatment approach for individuals affected by melanoma.
Dermatologische Klinik, Universitätsspital Zürich. reinhard.dummer@usz.ch
R
R
Dummer
S
S
Goldinger
J
J
Rinderknecht
N
N
Eggmann
L
L
Felderer
R
R
Braun
L E
LE
French
D000970:Antineoplastic Agents / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D018450:Disease Progression; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D008545:Melanoma / Q000235:genetics* / Q000628:therapy*; D011230:Precancerous Conditions / Q000235:genetics / Q000628:therapy; D057285:Precision Medicine; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics* / Q000628:therapy*; D012880:Skin Pigmentation / Q000235:genetics
D000970:Antineoplastic Agents; D019009:Proto-Oncogene Proteins c-kit; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf